Evolus commercializes Jeuveau (prabotulinumtoxinA-xvfs), an injectable aesthetic neurotoxin used to temporarily improve the appearance of moderate to severe glabellar (frown) lines. It positions itself as a specialist in medical aesthetics rather than a broad pharmaceutical portfolio company. Customers are primarily aesthetic physicians, dermatologists, and medspas seeking a Botox-class product with a consumer-facing brand strategy.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 68.5 | — | -18.9 | — |
| Q2 2025 | 69.4 | — | -17.1 | — |
| Q3 2025 | 69 | — | -15.7 | — |
| Q4 2025 | 90.3 | — | 0.1 | — |
| Q1 2026 | 73.1 | 6.7% | -10.7 | — |
| Q2 2026 | 84.1 | 21.2% | -8.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Euroseas Ltd. (ESEA), Apex Treasury Corporation (APXT), Entera Bio Ltd. (ENTX), 908 Devices Inc. (MASS), Neurogene Inc. (NGNE), Monopar Therapeutics Inc. (MNPR)